Long Term Follow-Up Study of a Randomized, Open-Label, Uncontrolled, Phase I/II Study to Assess the Safety and Immunogenicity of Intramuscular and Intradermal Doses of COVID-19 DNA Vaccine (AG0302-COVID19)

Long Term Follow-Up Study of a Randomized, Open-Label, Uncontrolled, Phase I/II Study to Assess the Safety and Immunogenicity of Intramuscular and Intradermal Doses of COVID-19 DNA Vaccine (AG0302-COVID19)

Pharmacological studies have demonstrated antibody production and infection prevention with an intradermal coronavirus disease 2019 (COVID-19) DNA vaccine (AG0302-COVID-19). This clinical trial aimed to investigate the safety and immunogenicity of high doses of AG0302-COVID19 when injected intramusc...

Full description

Bibliographic Details
Main Authors: Hironori Nakagami, Tetsuya Matsumoto, Kenji Takazawa, Hisakuni Sekino, Osamu Matsuoka, Satoshi Inoue, Hidetoshi Furuie, Ryuichi Morishita
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Vaccines
Subjects:
COVID-19
DNA vaccine
SARS-CoV-2
Online Access:https://www.mdpi.com/2076-393X/11/10/1535

Internet

https://www.mdpi.com/2076-393X/11/10/1535

Similar Items